US FDA extends review of Merus' gene-targeting cancer therapy-February 2024-www.financetom.com

US FDA extends review of Merus' gene-targeting cancer therapy

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA extends review of Merus' gene-targeting cancer therapy

Nov 5, 2024 6:18 AM

Nov 5 (Reuters) - The U.S. Food and Drug Administration

on Tuesday extended the review of Merus NV's ( MRUS )

gene-targeting cancer therapy to allow sufficient time to review

information submitted by the company.

The agency will now make a decision on the treatment by Feb.

4 2025, compared to a previous action date of November 6.

Previous page： --Street Color: Sysco Names CEO Kevin Hourican Chair Next page： Air Products and Chemicals Fiscal Q2 Adjusted Earnings Rise, Sales Fall; Sets Fiscal Q3 Adjusted EPS Outlook

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Street Color: Sysco Names CEO Kevin Hourican Chair

Apr 30, 2024

08:45 AM EDT, 04/30/2024 (MT Newswires) -- (Street Color news is derived from real time discussions with market professionals globally subscribed to the Street Color Premium Chat service on Bloomberg IB Chat and the ICE IM. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.) Price: 75.68, Change: -1.54, Percent...

Air Products and Chemicals Fiscal Q2 Adjusted Earnings Rise, Sales Fall; Sets Fiscal Q3 Adjusted EPS Outlook

Apr 30, 2024

08:44 AM EDT, 04/30/2024 (MT Newswires) -- Air Products and Chemicals ( APD ) reported fiscal Q2 adjusted earnings Tuesday of $2.85 per diluted share, up from $2.74 a year earlier. Analysts polled by Capital IQ expected $2.70. Sales for the quarter ended March 31 were $2.93 billion, down from $3.20 billion a year earlier. Analysts surveyed by Capital IQ...

TMX Group and Clearstream Launch Canadian Collateral Management Service

Apr 30, 2024

08:44 AM EDT, 04/30/2024 (MT Newswires) -- TMX Group ( TMXXF ) on Tuesday launched the Canadian Collateral Management Service (CCMS), the first domestic tri-party repo capability in the Canadian market Developed by TMX Group ( TMXXF ) and Clearstream, CCMS provides exclusive domestic tri-party repo capabilities to increase liquidity and minimize exposure risk. CCMS will help market participants solve...

Equitrans boosts cost estimate for Mountain Valley natgas pipe

Apr 30, 2024

April 30 (Reuters) - Equitrans Midstream Corp ( ETRN ) said on Tuesday it expects to complete the construction and final commissioning activities on its Mountain Valley natural gas pipeline by the end of May at an estimated cost of $7.85 billion. That is higher than the $7.57 billion to $7.63 billion cost estimate the company gave in February. Equitrans...